The role of polymorph nuclear neutrophils (PMN) in limb ischemia and reperfusion has been recognized only in recent years. The present study aimed to investigate the systemic and local (in femoral venous blood) effects of intra-arterially or intravenously applied prostaglandin E 1 (PGE 1 ) on systemic and ischemia-induced local changes in neutrophil function. Thirty patients with intermittent claudication were randomly assigned to intra-arterial or intravenous infusion of prostaglandin E 1 (10 g IA or 15 g IV over 30 min). Prior to infusion femoral arterial and venous blood samples were obtained from the predominantly affected leg under resting conditions and immediately after a 3-min period of ischemia induced by suprasystolic thigh compression. After 24 h additional blood samples were obtained at baseline, following infusion of prostaglandin E 1 , and again after another 3-min period of ischemia following the prostaglandin E 1 infusion.
Introduction
In peripheral arterial occlusive disease changes in the function of circulating neutrophils suggestive of cell activation have been reported. 1, 2 Furthermore, it has been shown that symptom limited walking exercise causes additional local alterations of neutrophil function. 3 Recent experimental results suggest that neutrophil activation causes stiffening of the cells and may promote interactions between leukocytes, platelets and endothelial cells. [4] [5] [6] [7] [8] These cell-cell interactions can trigger the release of toxic compounds, especially reactive oxygen metabolites from PMN, resulting in progressive microvascular dysfunction. 9, 10 Prostaglandin E 1 (PGE 1 ) has multiple effects on the microcirculatory level. 11, 12 It therefore offers novel therapeutic options in patients with peripheral arterial occlusive disease. 13 Although PGE 1 was introduced in clinical practice as early as 1973 by Carlson, the mode of action is not completely understood. 14 In experimental studies, 15, 16 as well as in patients with critical limb ischemia, 17 PGE 1 has been shown to inhibit neutrophil activation. This mechanism may contribute to the therapeutic effects of PGE 1 in patients with peripheral arterial occlusive disease. The purpose of the present study was to investigate the effects of intra-arterially and intravenously applied PGE 1 on systemic and ischemia-induced changes in neutrophil function in patients with peripheral arterial occlusive disease.
Methods

Patients
The study included 30 non-diabetic patients (24 male, 6 female; median age: 67 years, range: 46-76 years) with intermittent claudication and a pain-free walking distance of between 50 m and 150 m after treadmill testing (slope 12%, 3 km/h). Patients with significant iliac artery stenoses, inflammatory vessels diseases, or interfering nonangiologic diseases were not eligible for the study. The study was approved by the institutional ethics committee. Written informed consent was obtained from all patients.
Study protocol
After discontinuation of vasoactive substances for at least five half-lives of the respective drug the patients were randomly assigned to an intra-arterial or intravenous infusion with PGE 1 (Prostavasin ® , Schwarz Pharma AG, Monheim, Germany). On the first day of the trial the femoral artery and vein of the predominantly affected leg were cannulated with an 18 G flexible catheter (outer diameter 1.2 mm, length 10 cm). After a resting period of 20 min baseline blood samples were drawn from the catheters. Ischemia of the leg was then induced by a 3-min suprasystolic thigh compression with a plethysmography cuff, while the patients were moving the ischemic foot. The cuff was inflated to a pressure 30 mmHg above the systolic blood pressure measured at the upper arm. This procedure to induce ischemia was chosen to obtain a standardized and comparable degree of ischemia. Immediately after cuff deflation a second set of blood samples was obtained. The presence of ischemia was documented in all patients by demonstrating a significant increase in the arterial and venous difference of the lactate concentration (Boehringer, Mannheim, Germany). The ischemia-induced alteration in neutrophil function of the first day served as control for the influence of PGE 1 on neutrophil activation after ischemia on the second day of the study.
Having inserted arterial and venous lines in the femoral vessels for the second part of the trial, blood probes were sampled before and after infusion of vehicle for baseline examination. The patients then received an infusion of either 10 g PGE 1 in 50 ml 0.9% NaCl over 30 min into the femoral artery or 15 g PGE 1 in 50 ml 0.9% NaCl over 30 min into the femoral vein. Following the PGE 1 infusion a third set of blood samples was drawn after flushing the catheters with NaCl. Suprasystolic thigh compression with foot movements was then performed for 3 min, after which a fourth set of blood samples was obtained. Cuff pressure did not differ between day 1 and day 2.
Changes of neutrophil function in the arterial blood samples were interpreted as systemic effects, whereas changes in femoral venous blood probes, respectively arterial and venous blood differences, were seen as local effects.
Neutrophil tests
Radical production by leukocytes was assessed by measuring whole blood chemiluminescence. 18 The chemiluminescence assay was performed in a luminol enhanced system in a Wallac 1251 Luminometer (LKB, Tübingen, Germany). Heparinized blood measuring 50 l was mixed with 450 l of HEPES buffered DMEM (Dulbecco's modified eagle's medium) with 1 mol/l luminol (all reagents from Sigma, Deisenhofen, Germany) and incubated at 37°C for 5 min. Cells were stimulated with 1 mg/ml opsonized zymosan (Sigma) 5 and scintillation counting was performed immediately with repeat cycles of sequential 8-s counts. The integral of the photovoltage for the first 30 min after stimulation was taken as a measure of zymosan-stimulated whole blood chemiluminescence.
The proportion of activated neutrophils was assessed by the nitro blue tetrazolium (NBT) test. The NBT test was performed on freshly drawn heparinized samples (20 U/ml) with a modification of the method of Park et al. 19 The blood samples were incubated at 37°C for 15 min with an equal volume of an 0.1% solution of NBT (Sigma) in phosphate buffered saline (pH 7.2) and then kept at room temperature for another 15 min. Smears were prepared and stained by Wright's stain (Sigma). The percentage of neutrophils containing formazan deposits of at least the size of a lobe of the nucleus was designated as a positive NBT score.
Neutrophil filterability was assessed as described by 
Statistical analysis
Results are expressed as mean ± SEM unless otherwise indicated. Differences between matched samples were tested by the Wilcoxon matched-pairs signed-ranks test, and the 95% confidence intervals (Cl) for the mean difference were calculated. A level of significance at p Ͻ 0.05 in the two-tailed test was taken as significant.
Results
Changes in the arterial blood after PGE 1 Infusion of PGE 1 caused a significant decrease in zymosanstimulated whole blood chemiluminescence (Figure 1) in arterial blood. In this respect no difference between intraarterial and intravenous route of administration could be observed (Figure 1 ). The number of activated leukocytes (NBT test) tended to be lower after infusion of PGE 1 without reaching statistical significance ( Figure 2 ). Neutrophil filterability was not significantly influenced by either intraarterial or intravenous infusion of PGE 1 yet there seemed to be a trend towards lower filterabilities after treatment with PGE 1 (Figure 3 ). Infusion of PGE 1 independent of the application route resulted in a slight but significant increase in leukocyte count (Figure 4 ).
Ischemia-induced changes in neutrophil function
Under resting conditions with and without PGE 1 , none of the neutrophil parameters examined showed arterial and venous blood differences irrespective of PGE 1 . Ischemia, however, induced significant local changes under control conditions. Femoral venous neutrophil filterabilities were significantly lower ( Figure 5 ) and femoral venous NBT scores were significantly higher ( Figure 6 ) than those in the arterial blood. The presence of ischemia after suprasystolic thigh compression combined with foot movements was verified by a significant increase in the arterial and venous difference of the lactate concentration, which ranged from 0.51 to 2.43 mmol/l. The extent of ischemia did not differ between day 1 and day 2 regarding this parameter.
In patients treated with an intra-arterial infusion of prostaglandin E 1 the difference in neutrophil filterability between arterial and venous blood after ischemia was no longer statistically significant compared with data at rest and tended to be lower than under control conditions ( Figure 5 ). After intravenous infusion of prostaglandin E 1 , Vascular Medicine 1998; 3: 171-175 
Figure 5
Relative difference in neutrophil filterability between arterial and venous blood under resting conditions and after ischemia with and without PGE 1 . (95% Cl; *p Ͻ 0.05; n.s., not significant.) however, the trend towards a reduction of the ischemiainduced difference in neutrophil filterability between arterial and venous blood was considerably less prominent with significant local changes ( Figure 5 ). The local changes in NBT score after ischemia were not significantly affected by either intra-arterial or intravenous infusions of prostaglandin E 1 (Figure 6 ).
Ischemia also significantly augmented the release of oxygen radicals by PMN in all patients under control conditions. The relative difference of chemiluminescence values reached a level of 23.0 ± 13.2% in venous blood (p Ͻ 0.01) and 19.3 ± 8.4% (p Ͻ 0.01) in arterial blood. A significant difference in chemiluminescence between arterial and venous blood after ischemia was not observed, and was not affected by intra-arterially or intravenously administered PGE 1 .
Figure 6
Relative difference in NBT scores between arterial and venous blood under resting conditions and after ischemia with and without PGE 1 . (95% Cl; *p Ͻ 0.05, n.s., not significant.)
Discussion
The role of white blood cells and oxygen free radical generation in the development of arteriosclerosis has gained broad scientific attention. 21 The number of white blood cells is a powerful predictor of cardiovascular events. 2, 22 Radical generation and oxidative stress contribute to reperfusion injury after ischemia, and vascular damage due to this mechanism may also occur in PAOD. In patients with intermittent claudication an activation of neutrophils after symptom-limited exercise has been convincingly shown. 3 In vitro studies have shown that PGE 1 inhibits radical production by neutrophils. 15, 16 It has been suggested that this action might contribute to the beneficial effects of PGE 1 in the treatment of patients with peripheral arterial occlusive disease. 12, 15, 16 It is unknown, however, whether the inhibition of neutrophil function, shown in vitro, is also effective under clinical conditions after therapeutic administration of PGE 1 . Changes in the function of circulating leukocytes after infusion of PGE 1 are assessed by determination of neutrophil parameters in the arterial blood. The present study shows a reduction of leukocyte activation after both intra-arterial and intravenous infusions of PGE 1 in patients with intermittent claudication. This is shown by a significant decrease in zymosan-stimulated whole blood chemiluminescence. Furthermore, the proportion of activated neutrophils tended to be diminished by the infusion of PGE 1 . The findings of the present study concur with those of an earlier study in patients with critical limb ischemia. 17 In addition to the decrease in stimulated radical production a significant increase in leukocyte count was found, which may be explained by a shift of leukocytes from the marginating to the circulating pool. This shift may be caused by a reduced adhesive energy of marginating leukocytes or by an increase in shear stress due to PGE 1induced vasodilation. Because leukocyte adhesion contributes to the post-ischemic skeletal muscle injury, a reduction Vascular Medicine 1998; 3: 171-175 in the number of adherent leukocytes after ischemic exercise may also attenuate microvascular dysfunction. 9 Quantitatively the presumed admixture of leukocytes from the marginating pool does not suffice to account for the decrease in stimulated radical production, even assuming zero radical production by leukocytes from the marginating pool. It may, however, account for the trend towards a systemic decrease in neutrophil deformability. PGE 1 is almost completely metabolized during the first passage through the lung. 23 The systemic modulating effect of PGE 1 on neutrophil function may be attributed to active stable PGE 1 metabolites, such as 13, 14-dihydroprostaglandin E 1 . 24 Moreover, it has to be considered that exposure of neutrophils to PGE 1 prior to passage through the lung may be sufficient to exert a prolonged effect. 1 Local effects of PGE 1 in the diseased leg are reflected by the difference in neutrophil function between arterial and venous blood. Immediately after the intra-arterial infusion of PGE 1 significant differences in the measured parameters of PMN function between arterial and venous blood samples are not found. At this time, initial arterial and venous blood differences may be levelled out by recirculation during the infusion period. Intra-arterially applied PGE 1 , however, prevents the ischemia-induced local changes in neutrophil filterability. A similar effect is not observed after intravenous infusion of PGE 1 . Therefore the reduction of the ischemia-induced decrease of neutrophil deformability may not be explained by the effects of PGE 1 on circulating neutrophils alone, but also by action on other cell types within the leg, such as endothelial cells and/or macrophages.
Local effects of PGE
Conclusion
Intra-arterially and intravenously infused PGE 1 causes a systemic inhibition of zymosan-stimulated free radical production. Furthermore, intra-arterial infusion of PGE 1 appears to inhibit the local decrease of neutrophil deformability during subsequent episodes of ischemia. The modulating action of PGE 1 on leukocyte function may contribute to the beneficial effects in the treatment of patients with peripheral arterial occlusive disease.
